Targeting monoamine oxidase A for T cell–based cancer immunotherapy

Xi Wang(University of California, Los Angeles), Bo Li(University of California, Los Angeles), Kwang Gi Kim(University of California, Los Angeles), Yu-Chen Wang(University of California, Los Angeles), Zhe Li(University of California, Los Angeles), Jiaji Yu(University of California, Los Angeles), Samuel Zeng(University of California, Los Angeles), Xiaoya Ma(University of California, Los Angeles), In Young Choi(University of California, Los Angeles), Stefano Di Biase(University of California, Los Angeles), Drake J. Smith(University of California, Los Angeles), Yang Zhou(University of California, Los Angeles), Yan-Ruide Li(University of California, Los Angeles), Feiyang Ma(University of California, Los Angeles), Jie Huang(University of California, Los Angeles), Nicole Clarke(University of California, Los Angeles), Angela To(University of California, Los Angeles), Laura Gong(University of California, Los Angeles), Alexander Pham(University of California, Los Angeles), Heesung Moon(University of California, Los Angeles), Matteo Pellegrini(University of California, Los Angeles), Lili Yang(University of California, Los Angeles)
Science Immunology
May 14, 2021
Cited by 74

Abstract

expression with T cell dysfunction and decreased patient survival in a broad range of cancers. We further demonstrated that MAO-A restrains antitumor T cell immunity through controlling intratumoral T cell autocrine serotonin signaling. Together, these data identify MAO-A as an immune checkpoint and support repurposing MAOI antidepressants for cancer immunotherapy.


Related Papers

No related papers found

Powered by citation graph analysis